AU2009297113B2 - Derivatives of 1-amino-2-cyclobutylethylboronic acid - Google Patents

Derivatives of 1-amino-2-cyclobutylethylboronic acid Download PDF

Info

Publication number
AU2009297113B2
AU2009297113B2 AU2009297113A AU2009297113A AU2009297113B2 AU 2009297113 B2 AU2009297113 B2 AU 2009297113B2 AU 2009297113 A AU2009297113 A AU 2009297113A AU 2009297113 A AU2009297113 A AU 2009297113A AU 2009297113 B2 AU2009297113 B2 AU 2009297113B2
Authority
AU
Australia
Prior art keywords
substituted
independently
unsubstituted
aliphatic
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009297113A
Other languages
English (en)
Other versions
AU2009297113A1 (en
Inventor
Paul E. Fleming
Jing Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of AU2009297113A1 publication Critical patent/AU2009297113A1/en
Priority to AU2013204889A priority Critical patent/AU2013204889A1/en
Priority to AU2013204881A priority patent/AU2013204881A1/en
Priority to AU2013204874A priority patent/AU2013204874B2/en
Priority to AU2013204896A priority patent/AU2013204896A1/en
Application granted granted Critical
Publication of AU2009297113B2 publication Critical patent/AU2009297113B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
AU2009297113A 2008-09-29 2009-09-25 Derivatives of 1-amino-2-cyclobutylethylboronic acid Ceased AU2009297113B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2013204889A AU2013204889A1 (en) 2008-09-29 2013-04-12 Derivatives of 1-amino-2-cyclobutylethylboronic acid
AU2013204881A AU2013204881A1 (en) 2008-09-29 2013-04-12 Derivatives of 1-amino-2-cyclobutylethylboronic acid
AU2013204874A AU2013204874B2 (en) 2008-09-29 2013-04-12 Derivatives of 1-amino-2-cyclobutylethylboronic acid
AU2013204896A AU2013204896A1 (en) 2008-09-29 2013-04-12 Derivatives of 1-amino-2-cyclobutylethylboronic acid

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19461408P 2008-09-29 2008-09-29
US61/194,614 2008-09-29
PCT/US2009/005324 WO2010036357A1 (en) 2008-09-29 2009-09-25 Derivatives of 1-amino-2-cyclobutylethylboronic acid

Related Child Applications (4)

Application Number Title Priority Date Filing Date
AU2013204874A Division AU2013204874B2 (en) 2008-09-29 2013-04-12 Derivatives of 1-amino-2-cyclobutylethylboronic acid
AU2013204896A Division AU2013204896A1 (en) 2008-09-29 2013-04-12 Derivatives of 1-amino-2-cyclobutylethylboronic acid
AU2013204881A Division AU2013204881A1 (en) 2008-09-29 2013-04-12 Derivatives of 1-amino-2-cyclobutylethylboronic acid
AU2013204889A Division AU2013204889A1 (en) 2008-09-29 2013-04-12 Derivatives of 1-amino-2-cyclobutylethylboronic acid

Publications (2)

Publication Number Publication Date
AU2009297113A1 AU2009297113A1 (en) 2010-04-01
AU2009297113B2 true AU2009297113B2 (en) 2016-11-10

Family

ID=41426361

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009297113A Ceased AU2009297113B2 (en) 2008-09-29 2009-09-25 Derivatives of 1-amino-2-cyclobutylethylboronic acid

Country Status (25)

Country Link
US (3) US8664200B2 (enExample)
EP (1) EP2346882B1 (enExample)
JP (3) JP5736314B2 (enExample)
KR (1) KR101739470B1 (enExample)
CN (2) CN103554143B (enExample)
AR (1) AR075090A1 (enExample)
AU (1) AU2009297113B2 (enExample)
BR (1) BRPI0919447B8 (enExample)
CA (1) CA2739375C (enExample)
CL (1) CL2011000653A1 (enExample)
CO (1) CO6362015A2 (enExample)
CR (2) CR20160475A (enExample)
DO (1) DOP2011000086A (enExample)
EA (1) EA030539B1 (enExample)
EC (1) ECSP11011011A (enExample)
IL (1) IL211983A0 (enExample)
MA (1) MA32729B1 (enExample)
MX (1) MX2011003317A (enExample)
MY (1) MY166653A (enExample)
NZ (2) NZ606001A (enExample)
SG (1) SG194388A1 (enExample)
TW (2) TW201024313A (enExample)
UA (1) UA105503C2 (enExample)
WO (1) WO2010036357A1 (enExample)
ZA (1) ZA201203615B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101434522B1 (ko) 2005-11-09 2014-08-26 오닉스 세라퓨틱스, 인크. 효소 저해를 위한 화합물
US7691852B2 (en) 2006-06-19 2010-04-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
RS54847B2 (sr) 2007-10-04 2019-09-30 Onyx Therapeutics Inc Inhibitori kristalne peptid epoksi keton proteaze i sinteza aminokiselinskih keto-epoksida
EP2730580A1 (en) 2008-06-17 2014-05-14 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
JP5675629B2 (ja) 2008-10-21 2015-02-25 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンを用いた併用療法
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
MA34133B1 (fr) * 2010-03-01 2013-04-03 Onyx Therapeutics Inc Composes pour inhibiteurs de l'immunoproteasome
UA110612C2 (uk) 2010-03-31 2016-01-25 Мілленніум Фармасьютікалз, Інк. Похідні 1-аміно-2-циклопропілетилборонової кислоти
JP6286358B2 (ja) 2011-11-11 2018-02-28 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤に応答するバイオマーカー
CA2855356A1 (en) 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
EA201400735A1 (ru) * 2011-12-22 2015-04-30 Арес Трейдинг С.А. Производные альфа-амино бороновой кислоты, селективные ингибиторы иммунопротеасомы
EP2810066B1 (en) 2012-01-24 2019-07-31 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
CN104822689B (zh) * 2012-12-03 2016-11-02 弗·哈夫曼-拉罗切有限公司 取代的三唑硼酸化合物
KR20160058886A (ko) 2013-10-03 2016-05-25 밀레니엄 파머슈티컬스 인코퍼레이티드 전신 홍반성 낭창 및/또는 낭창성 신염의 예방 또는 치료 방법
ES2748434T3 (es) 2014-01-10 2020-03-16 Univ Cornell Dipéptidos como inhibidores de inmunoproteasomas humanos
KR102509950B1 (ko) 2014-05-20 2023-03-14 밀레니엄 파머슈티컬스 인코퍼레이티드 일차 암 치료법 후 사용하기 위한 붕소-함유 프로테아좀 저해제
US10301273B2 (en) 2014-08-07 2019-05-28 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
CN114796207A (zh) 2014-08-18 2022-07-29 康奈尔大学 作为人免疫蛋白酶体的抑制剂的二肽模拟物
BR112017006368A2 (pt) * 2014-10-01 2017-12-19 Merck Patent Gmbh derivados de ácido borônico
BR112017006349A2 (pt) * 2014-10-01 2017-12-12 Merck Patent Gmbh derivados de ácido borônico
WO2016050359A1 (en) * 2014-10-01 2016-04-07 Merck Patent Gmbh Boronic acid derivatives
SG11201702628XA (en) * 2014-10-01 2017-04-27 Merck Patent Gmbh Boronic acid derivatives
CN108351169B (zh) 2015-10-15 2022-01-28 康奈尔大学 蛋白酶体抑制剂及其用途
EP3472151A4 (en) 2016-06-21 2020-03-04 Orion Ophthalmology LLC CARBOCYCLIC PROLINAMIDE DERIVATIVES
ES2971784T3 (es) 2016-06-21 2024-06-07 Orion Ophthalmology LLC Derivados heterocíclicos de prolinamida
EP3589659B1 (en) 2017-02-28 2025-04-09 Mayo Foundation for Medical Education and Research Combinations for use in the treatment of cancer
WO2019075252A1 (en) 2017-10-11 2019-04-18 Cornell University PEPTIDOMIMETIC INHIBITORS OF PROTEASOME
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
LT3952995T (lt) 2019-04-12 2023-11-10 Riboscience Llc Bicikliniai heteroarilo dariniai kaip ektonukleotidų pirofosfatazės fosfodiesterazės 1 inhibitoriai

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021558A2 (en) * 2003-08-14 2005-03-10 Cephalon, Inc. Proteasome inhibitors and methods of using the same

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ203706A (en) 1982-04-22 1986-03-14 Squibb & Sons Inc Occlusive multi-layer wound dressing and hydrocolloidal granules for wound treatment
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5159060A (en) 1988-05-27 1992-10-27 Mayo Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
DE3827340A1 (de) 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
DE69217935T2 (de) 1992-08-14 1997-10-09 Procter & Gamble Alpha-aminoborsäurehaltige flüssige Waschmittel
US5492900A (en) 1993-09-10 1996-02-20 Neutron Technology Corporation Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA)
US5935944A (en) 1993-09-10 1999-08-10 Neutron Technology Corporation Formulation for I.V. administration of the boron delivery drug, boronophenylalanine (BPA)
US6060462A (en) 1993-10-20 2000-05-09 Dupont Pharmaceuticals Company Electrophilic peptide analogs as inhibitors of trypsin-like enzymes
US5574017A (en) 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
CA2281224A1 (en) 1997-02-15 1998-08-20 Proscript, Inc. Treatment of infarcts through inhibition of nf-kappab
JP2001517631A (ja) 1997-09-25 2001-10-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症疾患および自己免疫疾患を治療するためのプロテアソーム阻害剤、ユビキチン経路阻害剤、またはユビキチンプロテアソーム経路を介したＮＦ−κＢの活性化に干渉する剤
CA2314259A1 (en) 1997-12-16 1999-06-24 Robert Siman Multicatalytic protease inhibitors for use as anti-tumor agents
US6169076B1 (en) 1999-03-31 2001-01-02 Glcosyn Pharmaceuticals, Inc. P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols
AU5788800A (en) 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
US6699835B2 (en) 2001-01-25 2004-03-02 The United States Of America As Represented By The Department Of Health And Human Services Formulation of boronic acid compounds
ATE317850T1 (de) 2001-05-30 2006-03-15 Novartis Pharma Gmbh 2-((n-(2-amino-3-(heteroaryl- oder - aryl)propionyl)aminoacyl)amino)- alkylboronsäurederivate
JPWO2003033507A1 (ja) 2001-10-12 2005-02-03 杏林製薬株式会社 ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬
JP4412586B2 (ja) 2002-01-08 2010-02-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 エポネマイシンおよびエポキソマイシン類似物およびそれらの用途
AU2003223930A1 (en) 2002-06-14 2003-12-31 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
US20060084592A1 (en) 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
MY162518A (en) * 2003-08-14 2017-06-15 Cephalon Inc Proteasome inhibitors and methods of using the same
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
GB0405267D0 (en) 2004-03-09 2004-04-21 Trigen Ltd Compounds
ES2899606T3 (es) 2004-03-30 2022-03-14 Millennium Pharm Inc Síntesis de compuestos de ésteres y ácidos borónicos
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
EP1898899A4 (en) 2005-07-05 2009-07-29 Tufts College INHIBITORS OF THE FIBROBLAST ATTACHMENT PROTEIN ALPHA
WO2007089618A2 (en) 2006-01-27 2007-08-09 Phenomix Corporation Hepatitis c serine protease inhibitors and uses therefor
WO2009006473A2 (en) 2007-07-05 2009-01-08 Trustees Of Tufts College Pro-soft polypeptide proteasome inhibitors, and methods of use thereof
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
CN101772507B (zh) 2007-08-06 2012-12-12 米伦纽姆医药公司 蛋白酶体抑制剂
EP2730580A1 (en) 2008-06-17 2014-05-14 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
UA110612C2 (uk) 2010-03-31 2016-01-25 Мілленніум Фармасьютікалз, Інк. Похідні 1-аміно-2-циклопропілетилборонової кислоти

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021558A2 (en) * 2003-08-14 2005-03-10 Cephalon, Inc. Proteasome inhibitors and methods of using the same

Also Published As

Publication number Publication date
EP2346882A1 (en) 2011-07-27
US20100081633A1 (en) 2010-04-01
SG194388A1 (en) 2013-11-29
TWI598352B (zh) 2017-09-11
AR075090A1 (es) 2011-03-09
JP2012504122A (ja) 2012-02-16
US8664200B2 (en) 2014-03-04
NZ606001A (en) 2014-08-29
ZA201203615B (en) 2015-03-25
MA32729B1 (fr) 2011-10-02
CN103554143A (zh) 2014-02-05
CN102203103A (zh) 2011-09-28
KR101739470B1 (ko) 2017-05-24
CR20110216A (es) 2011-07-14
AU2009297113A1 (en) 2010-04-01
EP2346882B1 (en) 2017-09-20
MY166653A (en) 2018-07-18
WO2010036357A1 (en) 2010-04-01
TW201641504A (zh) 2016-12-01
MX2011003317A (es) 2011-04-26
CR20160475A (es) 2016-12-19
CO6362015A2 (es) 2012-01-20
EA030539B1 (ru) 2018-08-31
TW201024313A (en) 2010-07-01
BRPI0919447A2 (pt) 2015-12-15
IL211983A0 (en) 2011-06-30
BRPI0919447B8 (pt) 2021-05-25
US20170349611A1 (en) 2017-12-07
CN103554143B (zh) 2018-02-23
CA2739375C (en) 2019-03-12
DOP2011000086A (es) 2011-04-15
US20140194387A1 (en) 2014-07-10
JP2017025091A (ja) 2017-02-02
CA2739375A1 (en) 2010-04-01
KR20110082534A (ko) 2011-07-19
EA201170508A1 (ru) 2011-10-31
BRPI0919447B1 (pt) 2021-03-30
UA105503C2 (uk) 2014-05-26
NZ592497A (en) 2013-02-22
JP2015143264A (ja) 2015-08-06
US10035811B2 (en) 2018-07-31
US9771381B2 (en) 2017-09-26
ECSP11011011A (es) 2011-07-29
CL2011000653A1 (es) 2011-09-30
JP5736314B2 (ja) 2015-06-17

Similar Documents

Publication Publication Date Title
AU2009297113B2 (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
AU2011235227B2 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
AU2013204874B2 (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
AU2013204868B2 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
HK1160140A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
HK1160140B (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
HK1194384A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired